ICE
Checked 2026-09-09
Relapsed or refractory aggressive lymphoma and Hodgkin lymphoma, salvage and stem cell mobilisation before autologous transplant (R-ICE when rituximab is added)
One cycle
every 14 days × 2-3 · about 4 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 100 mg/m² | IV | D1-3 | |
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 5 (maximum 800 mg) | IV | D2 | |
Ifosfamide Cytotoxic chemotherapy (alkylating agent) | 5,000 mg/m² with mesna | IV | D2 (24 h infusion) |
Cycles
2-3
14-day cycle
Emetogenicity
High (>90%)
G-CSF
Built into the protocol
Notes
- Mesna and hydration for ifosfamide; watch for ifosfamide encephalopathy.
- For early-relapsing large B-cell lymphoma CAR-T has replaced salvage chemotherapy and transplant (ZUMA-7, TRANSFORM).
Used in
Products
Source
Moskowitz, JCO 1999: ICE as second-line therapy before transplant
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
R-CHOP
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
every 21 days × 6
Pola-R-CHP
Untreated DLBCL, IPI 2-5
every 21 days × 6
R-ICE
Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging
every 14 days × 2-3
ABVD
Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage
every 28 days × 2-6
BV-AVD
Stage III-IV classical Hodgkin lymphoma
every 28 days × 6
N-AVD (nivolumab + AVD)
Stage III-IV classical Hodgkin lymphoma, age 12 and above
every 28 days × 6
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days
CHOP
Peripheral T-cell lymphomas first line (often with etoposide as CHOEP, or brentuximab replacing vincristine for CD30-positive disease); the historical backbone of R-CHOP in B-cell lymphoma
every 21 days × 6